Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY23 results · Jul–Sep 2022
Solara Active Pharma Sciences reported revenue from operations of ₹338.37 crore (down 15.7% from Q2 FY22) and net loss of ₹9.98 crore for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 338.37 | 401.61 | −15.7% | 330.07 | +2.5% |
| Other income | 3.72 | 3.31 | +12.4% | 6.98 | −46.7% |
| Total income | 342.09 | 404.92 | −15.5% | 337.05 | +1.5% |
| Profit before tax | (19.30) | 29.68 | Turned loss | (31.10) | Loss narrowed |
| Net profit for the period | (9.98) | 29.68 | Turned loss | (16.45) | Loss narrowed |
| Attributable to shareholders of the company | (9.96) | 29.71 | Turned loss | (16.43) | Loss narrowed |
| EPS, basic (₹) | (2.77) | 8.27 | Turned loss | (4.56) | Loss narrowed |
| Net margin (%) | -2.9 | 7.4 | -5.0 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 338.37 | 401.61 | −15.7% | 330.07 | +2.5% |
| Other income | 3.77 | 3.51 | +7.4% | 6.48 | −41.8% |
| Total income | 342.14 | 405.12 | −15.5% | 336.55 | +1.7% |
| Profit before tax | (19.23) | 30.23 | Turned loss | (34.39) | Loss narrowed |
| Net profit for the period | (9.91) | 30.23 | Turned loss | (19.18) | Loss narrowed |
| EPS, basic (₹) | (2.75) | 8.42 | Turned loss | (5.33) | Loss narrowed |
| Net margin (%) | -2.9 | 7.5 | -5.8 |
Consolidated
- Filed with BSE
- 10 Nov 2022, 16:26 IST
- Board meeting
- 09 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Nov 2022, 16:26 IST
- Board meeting
- 09 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE